Login to Your Account



$105M More in Reworked Mitsubishi Deal

Nearing Telaprevir Endgame, Vertex Bulks up War Chest

By Jennifer Boggs


Friday, July 31, 2009
Approaching the last leg of development with hepatitis C drug telaprevir, Vertex Pharmaceuticals Inc. continues to shore up its balance sheet in preparation of the product's U.S. launch, which, if all goes well, could come in early 2011. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription